Original title: Hybrid organometallic galectin inhibitors
Authors: Hamala, Vojtěch
Document type: Papers
Conference/Event: Bažant Postgraduate Conference 2022, Prague (CZ), 20220613
Year: 2022
Language: eng
Abstract: Galectins are lectin-type proteins defined by their sequence homology and the ability to bind β-galactosides. Human galectin-1 (Gal-1) and galectin-3 (Gal-3) are involved in tumor progression. Elevated Gal-1 levels are reported for many tumor tissues and Gal-1 contributes to tumor progression including cell migration and tumor immune escape.\nGal-3 is characteristically overexpressed in many cancers and an elevated Gal-3 level is associated with increased invasiveness, metastatic spreading, immunosuppression and angiogenesis. Galectins are also implicated in progression of serious diseases other than cancer e.g., cardiovascular ones, diabetes mellitus, fibrosis, and others. These\nproperties make galectins promising therapeutic targets.\n
Keywords: galectin inhibitors; glycomymetics; organometallic compounds
Host item entry: Proceedings of Abstracts, ISBN 978-80-86186-24-5
Rights: This work is protected under the Copyright Act No. 121/2000 Coll.

Institution: Institute of Chemical Process Fundamentals AS ČR (web)
Original record: http://hdl.handle.net/11104/0332205

Permalink: http://www.nusl.cz/ntk/nusl-508661


The record appears in these collections:
Research > Institutes ASCR > Institute of Chemical Process Fundamentals
Conference materials > Papers